Your body stores fat for energy but can hold onto it stubbornly, especially around the belly. Appetite signals often make it hard to eat less. AOD-9604 is a small fragment of human growth hormone that has been studied for its potential to directly promote fat breakdown (lipolysis). GLP receptor agonists — semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound), and the newer retatrutide — powerfully reduce hunger and calorie intake. Many explore combining them so GLPs handle appetite while AOD-9604 helps release stored fat. No large primary trials test the exact stack, but individual studies support complementary actions. This article uses peer-reviewed clinical data.
What Are These Compounds?
- AOD-9604 is the last 16 amino acids of growth hormone, chosen for its fat-burning part. It does not raise IGF-1 or affect blood sugar like full growth hormone.
- Semaglutide is a GLP-1 receptor agonist (once-weekly injection).
- Tirzepatide is a dual GLP-1/GIP agonist.
- Retatrutide is an investigational triple agonist (GLP-1/GIP/glucagon).
The stack idea: GLPs create a big calorie deficit by suppressing appetite; AOD-9604 mobilizes fat stores so the body burns them more easily.
AOD-9604: Fat Mobilization Without Major Side Effects
AOD-9604 stimulates lipolysis (fat breakdown) in fat cells. In obese mice, it reduced body weight and fat, particularly via beta-3 adrenergic pathways, without impairing insulin sensitivity.
Human trials (over 900 people total, 2001–2007): It appears most useful for supporting fat metabolism rather than dramatic standalone weight loss. Therefore, we recommend it when combined with another peptide, such as a GLP-1.
GLP Agonists: Powerful Appetite Suppression and Weight Loss
These drugs mimic gut hormones that tell your brain you are full and slow digestion.
- Semaglutide (STEP 1 trial): 2.4 mg weekly led to ~15% body weight loss over 68 weeks vs. 2.4% with placebo. It also reduced cardiovascular events in the SELECT trial.
- Tirzepatide (SURMOUNT-1): Up to 21% weight loss at 72 weeks (highest dose), with major improvements in blood sugar, blood pressure, and lipids.
- Retatrutide (Triump phase 3): Up to 16–29% weight loss in diabetes and obesity studies, with continued loss and strong A1C reductions. It adds glucagon action for extra energy expenditure, fat lypolysis.
Why Stack Them? Potential Synergy for Fat Loss
- GLPs create a large calorie deficit by reducing hunger and food intake.
- AOD-9604 may help the body actually mobilize and burn stored fat (especially stubborn areas) during that deficit.
Clinics and researchers note this could lead to better body composition (more fat loss, less muscle loss) than GLPs alone. The mechanisms complement each other: appetite control + direct lipolysis. No large randomized combo trials yet, but the logic is sound, and early real-world use is discussed positively.
Important Caveats from the Science
GLPs (especially semaglutide and tirzepatide) have the strongest, largest human evidence and are FDA-approved for weight management. AOD-9604 is safe in trials but showed only modest or inconsistent weight loss in larger studies. It remains a research compound in many places. Long-term safety of the unregulated stack is unknown. The quality of compounded peptides varies. These are tools — not magic — and work best with diet, exercise, and medical supervision. Common GLP side effects are gastrointestinal; AOD-9604 has few reported. Always consult a doctor.
The Bottom Line
Primary studies show AOD-9604 supports fat mobilization through lipolysis pathways with a clean safety profile, while semaglutide, tirzepatide, and retatrutide deliver strong appetite suppression and impressive weight loss in large trials. Together, they target two key problems — eating less and burning stored fat — for potential synergistic results. A promising approach for improved fat loss and body composition. Science keeps advancing tools to help people manage weight more effectively and sustainably. The field of medicine and peptides is truly exciting.This information is not medical advice. Results vary by individual, and these compounds should be used only under the supervision of a qualified healthcare provider with appropriate monitoring (including regular bloodwork). They are not substitutes for a healthy diet, exercise, sleep, or standard medical care. Always consult your doctor before starting any peptide or compounded regimen.
